Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
作者： Roberto Würth , Stefano Thellung , Adriana Bajetto , Michele Mazzanti , Tullio Florio
DOI: 10.1016/J.DRUDIS.2015.09.017
关键词: Computational biology 、 Drug 、 Cancer therapy 、 Drug discovery 、 Repurposing 、 Molecular targets 、 Cancer stem cell 、 Cancer 、 Pharmacology 、 Drug repositioning 、 Medicine
摘要: … Several studies reveal the benefits of daily aspirin on multiple aspects of cancer … of low-dose aspirin for VTE prophylaxis in patients with multiple myeloma treated with thalidomide or …
core.ac.uk
sci-hub.se 
researchgate.net 参考文章(127)
Enza Lonardo, Michele Cioffi, Patricia Sancho, Shanthini Crusz, Christopher Heeschen, Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies Journal of Visualized Experiments. ,(2015) , 10.3791/52801
Joanna Triscott, Mary Rose Pambid, Sandra E. Dunn, Concise Review: Bullseye: Targeting Cancer Stem Cells to Improve the Treatment of Gliomas by Repurposing Disulfiram Stem Cells. ,vol. 33, pp. 1042- 1046 ,(2015) , 10.1002/STEM.1956
J Yang, J Wei, Y Wu, Z Wang, Y Guo, P Lee, X Li, Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer Oncogenesis. ,vol. 4, ,(2015) , 10.1038/ONCSIS.2015.18
Roberto Würth, Alessandra Pattarozzi, Monica Gatti, Adirana Bajetto, Alessandro Corsaro, Alessia Parodi, Rodolfo Sirito, Michela Massollo, Cecilia Marini, Gianluigi Zona, Daniela Fenoglio, Gianmario Sambuceti, Gilberto Filaci, Antonio Daga, Federica Barbieri, Tullio Florio, Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle. ,vol. 12, pp. 145- 156 ,(2013) , 10.4161/CC.23050
6. Yue W1, Zheng X1, 2, Lin Y1, 3, Yang CS1, 3, Xu Q4, Carpizo D1, Huang H4, 5, DiPaola RS1, Tan XL1, None, Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2 Oncotarget. ,vol. 6, pp. 21208- 21224 ,(2015) , 10.18632/ONCOTARGET.4126
Marta Gritti, Roberto Würth, Marina Angelini, Federica Barbieri, Marta Peretti, Erika Pizzi, Alessandra Pattarozzi, Elisa Carra, Rodolfo Sirito, Antonio Daga, Paul M.G. Curmi, Michele Mazzanti, Tullio Florio, Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current Oncotarget. ,vol. 5, pp. 11252- 11268 ,(2014) , 10.18632/ONCOTARGET.2617
H Yang, L Pellegrini, A Napolitano, C Giorgi, S Jube, A Preti, C J Jennings, F De Marchis, E G Flores, D Larson, I Pagano, M Tanji, A Powers, S Kanodia, G Gaudino, S Pastorino, H I Pass, P Pinton, M E Bianchi, M Carbone, Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression Cell Death and Disease. ,vol. 6, ,(2015) , 10.1038/CDDIS.2015.153
S Jagannathan, M A Y Abdel-Malek, E Malek, N Vad, T Latif, K C Anderson, J J Driscoll, Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib Leukemia. ,vol. 29, pp. 2184- 2191 ,(2015) , 10.1038/LEU.2015.157
Richard E. Kast, Georg Karpel-Massler, Marc-Eric Halatsch, CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. ,vol. 5, pp. 8052- 8082 ,(2014) , 10.18632/ONCOTARGET.2408
Yu Sun, Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Medicinal Research Reviews. ,vol. 35, pp. 408- 436 ,(2015) , 10.1002/MED.21338